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Abstract
Background and purpose: Lonidamine is a hexokinase II inhibitor, works as an anticancer molecule, and is
extensively explored in clinical trials. Limited information prevails about the stability-indicating methods
which could determine the forced degradation of lonidamine under stressed conditions. Hence, we report the
use of a rapid, sensitive, reproducible, and highly accurate liquid chromatography and mass spectrometry
method to analyze lonidamine degradation.
Experimental approach: The Xbridge BEH shield reverse phase C18 column (2.5 µm, 4.6 × 75 mm) using
isocratic 50:50 water: acetonitrile with 0.1% formic acid can detect lonidamine with help of mass spectrometer
in tandem with an ultraviolet (UV) detector at 260 nm wavelength.
Findings/ Results: A linear curve with r² > 0.99 was obtained for tandem liquid chromatography-mass
spectrometry (LC-MS)-UV based detections. This study demonstrated (in the present set up of isocratic
elution) that LC-MS based detection has a relatively high sensitivity (S/N (10 ng/mL): 220 and S/N (20
ng/mL): 945) and accuracy at lower detection and quantitation levels, respectively. In addition to developing
the LC-MS method, we also report that the current method is stability-indicating and shows that lonidamine
gets degraded over time under all three stress conditions; acidic, basic, and oxidative.
Conclusion and implications: LC-MS based quantitation of lonidamine proved to be a better method
compared to high-performance liquid chromatography (HPLC)-UV detections for mapping lonidamine
degradation. This is the first report on the stability-indicating method for studying the forced degradation of
lonidamine using LC-MS method.

Keywords: Forced degradation; LC-MS; Lonidamine; Stability indicating.
INTRODUCTION
Approximately 1.7 million U.S. individuals
are diagnosed with cancer each year and nearly
half will die from the disease, according to data
from the National Institute of Health (1,2). The
rapidly growing nature of cancer cells indicates
that cancer is an energy-dependent phenomenon.
In the late 1990s, it was suggested that this rapid
proliferation resulted from increased expression
of genes coding for glucose transporters and
glycolytic enzymes in tumor cells (3).
The glycolysis hypothesis provided an
opportunity for cancer researchers to explore
*Corresponding author: G. Kaushal
Tel: +1-2155032025, Fax: +1-2155033082
Email: gagan.kaushal@jefferson.edu

the use of novel and targeted therapies (4,5). In
particular, they targeted hexokinase II (HKII), a
protein that performs catalysis of the first step
of glycolysis. Along with porin (a
mitochondrial protein), it prevents the release
of cytochrome C during apoptosis cascade.
Research showed that the depletion of HKII in
cancer cells increases the concentration of
reactive oxygen species (ROS), which leads to
cell death (6).
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conducted with HPLC with limited information
about the degradation profile of lonidamine.
Our research indicates that LC-MS based
methods for quantitation of pharmaceutical
active ingredients and their metabolites can
prove to be significantly sensitive (23,24). In
the current work, we demonstrated a highly
sensitive LC-MS method for quantitating
lonidamine using single or selected ion
monitoring (SIM) mode. Results showed
improved sensitivity of LC-MS over HPLCultraviolet (UV) detection. Finally, the assay
was used to quantitatively assess the
degradation profile of lonidamine under strong
acidic, basic, oxidative stress conditions.

Furthermore, the presence of certain HKII
inhibitors causes detachment of HKII enzyme
from mitochondria, which leads to cell death by
a drastic reduction in ATP (7,8). This makes
HKII protein an important drug target for nextgeneration anticancer therapy. Three molecules
that inhibit HKII have been studied for their
anticancer effects including 2-deoxyglucose,
3-bromopyruvate, and clotrimazole (5).
Researchers have also studied the anticancer
potential of lonidamine (2-indole-carboxylic
acid) as HKII inhibitor. It selectively reduces
glycolysis of tumor cells, possibly by inhibiting
mitochondrial-bound hexokinase, which is
absent in normal differentiated cells (9,10).
Lonidamine also reduces lactate production in
B-cell chronic leukemia, possibly due to
reduced cellular ATP (which is required for
glycolysis) (11). Furthermore, lonidamine has
been shown to improve the sensitivity of cancer
cells to known anticancer drugs such as
doxorubicin, cisplatin, melphalan, and others
(12-15). As a result, this molecule was explored
in phase I and II clinical trials in combination
therapy against breast cancer, glioblastoma
multiforme, ovarian cancer, and lung cancer
(16). Lonidamine was well-tolerated but
limited by poor bioavailability after oral
administration.
In light of this poor bioavailability,
lonidamine is currently been explored in
microencapsulation and targeted nanoparticlebased strategies to improve its delivery (17-18).
Current methods for quantifying lonidamine are
limited, particularly at the lower concentrations
employed
in
preclinical
experiments.
Lonidamine is usually quantified using
conventional
high-performance
liquid
chromatography (HPLC) assays in biological
fluids and samples (19). Most HPLC methods
have relatively high limits of detection and
quantitation levels, indicating relatively low
sensitivities at lower concentrations (20-22).
Newer high-resolution mass spectrometers and
ultra HPLC systems can aid in developing
highly sensitive assays for the quantitation of
lonidamine. To the best of our knowledge,
LC-MS method has not been used to quantify
lonidamine for analytical applications.
Furthermore, the best-known method for
studying the stability study of lonidamine was

MATERIALS AND METHODS
Chemicals and reagents
Lonidamine was procured from Sigma
Aldrich (St. Louis, MO, USA). LC-MS grade
acetonitrile, water, and formic acid were
purchased from Fischer Scientific (Fair Lawn,
NJ, USA). XBridge C18 reverse phase (RP)
HPLC column was procured from Waters Corp.
(Milford, MA, USA). Sodium hydroxide pellets
NF, hydrochloric acid, and hydrogen peroxide
were purchased from Fisher Chemicals
(Fair Lawn, NJ, USA).
Liquid chromatography conditions
A lonidamine quantitation assay was
established using an isocratic elution method
with 50:50 acetonitrile with 0.1% formic acid
and water with 0.1% formic acid as a mobile
phase. The sample injection was set to 20 µL
with a flow rate of 0.350 mL/min. The
temperature of the column was maintained at
30 °C with constant data acquisition for 20 min
of run time. Ultra-high-performance LC-MS
(UHPLC-MS) in tandem with UV (260 nm
wavelength) was used for developing
the quantitation method. Here, a Dionex
3000 UHPLC system (USA) was used for
developing the tandem UHPLC-MS-UV
method. The HPLC was a quaternary pump
system with autosampler, column oven, and
temperature-controlled sample tray. Exactive
(v 1.1SP6) software was used for MS method
development and data acquisition. Thermo
Excaliber (v 3.0.63) was used for the
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(25). The mean value of the lower limit of
quantitation (LLOQ) was set within ± 10%
coefficient of variance (CV). For other (higher)
concentrations, this limit was set to ± 5% CV.
According to Moorthy et al. at least 75% of the
non-zero standards should meet these criteria
and the linear coefficient of determination (r2)
should be ≥ 0.99 (26). A linear regression
(Y = mX + C) equation was determined for both
data sets from concentration vs area of
calibration standards. A linear regression
equation from LC-MS standard runs was used
to determine the time-dependent degradation of
lonidamine under various forced degradation
conditions.

integration of Chromeleon and Exactive for
sample injections and LC-MS data acquisition
in .raw format.
Mass spectrometry conditions
For identification of analyte (lonidamine) in
solution eluting out of the HPLC column, a
mass scanning range of 100 to 322 m/z was
used. All scans were performed under positive
ion mode. The sheath gas flow rate was
maintained at 30 psi with an electron spray
ionization voltage of 3.50 kV and a capillary
temperature of 380 °C. Capillary, tube lens, and
skimmer voltages were maintained at 45, 85,
and 18 V, respectively. These parameters were
adjusted using the auto-tune function of
Thermo Exactive (v. 1.1 Sp6) software by
direct infusion of lonidamine in the mass
spectrometer. Using this function, the software
automatically adjusts the parameters mentioned
above to optimize the signal-to-noise (S/N)
ratio (around 107 units) for lonidamine. Hence,
an offline MS method was developed for the
identification of lonidamine, which was then
integrated with LC to develop quantitation and
stability-indicating methods.

Validation and stability
The quantitative method for LC-MS was
validated for inter- and intra-day accuracy,
%CV, and stability. Validation of the method
was carried out using quality control (QC)
standards of four random concentrations (80,
200, 3000, and 8000 ng/mL). Measurements
were made for inter- and intra-day %CV and %
accuracy. Furthermore, to check the stability of
solutions, LC-MS analysis for lonidamine at
various concentrations (20, 40, 500, and 10,000
ng/mL) were performed after freeze (-20°C)thaw cycles.

Sample preparation
Primary stocks of lonidamine were prepared
in methanol (LC-MS grade) at a concentration
of 1 mg/mL and stored at -20 °C. This aliquot
was used for making secondary stock of
10 µg/mL. Later, the secondary stock solution
was serially diluted in the concentration range
of 10 to 10,000 ng/mL. All the serially diluted
samples were stored at 4 °C for inter-day runs.
All inter- and intra-day runs were performed at
20 °C. All the serially diluted samples were
subjected to LC-MS-UV tandem runs.

Acid degradation studies of lonidamine
Preliminary studies have shown that
lonidamine degrades at 1 µg/mL under 1 N HCl
at 40 °C (28,29). Hence to assess the rate of
degradation and probable degradation peaks of
lonidamine, it was subjected to forced
degradation with 1 N HCl under 40 and 80 °C
with a final volume of solution as 10 mL.
Samples (100 µL) were withdrawn at specific
time (0, 6, 24, 48, and 72 h) points, centrifuged
at 15,700 g for 10 min, and subjected to LC-MS
runs to identify probable degradation
chromatograms.

Linearity
A linearity curve (for LC-MS and
HPLC-UV) was prepared for the calibration
standard samples (10 to 10,000 ng/mL) using
values from three independent day runs, with
two repeated injection for each set, n = 6 (3 ×
2) injections. While developing the quantitation
assay, the acceptable mean value of estimated
concentration (% accuracy or recovery) for
calibration and validation standards were kept
within ± 15% to ± 20% of the theoretical value

Alkali degradation studies of lonidamine
Similar to acidic degradation, lonidamine
can also degrade under alkaline conditions. In
order to assess the degradation process,
lonidamine was treated with 1 N NaOH under
40 and 80 °C with a final volume (of solution)
of 10 mL. Samples (100 µL) were withdrawn at
314
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specific time (0, 6, 24, 48, and 72 h) points,
centrifuged at 15,700 g for 10 min, and
subjected to LC-MS runs to identify probable
degradation peaks in the chromatogram.

RESULTS
Method development for the quantitative
determination of lonidamine
The retention time of standard lonidamine
was found to be 12.34 ± 0.4 min with selected
or targeted mass (M+H) + ion as 321.02 m/z, as
shown in Fig. 1. The linearity equation
(Y = 32792X) was established with correlation
coefficient (r2) 0.9959. The average accuracy of
inter- and intra-day run was found to be 88.14
± 0.568% to 115.577 ± 0.469%, respectively. In
the case of LC-MS method, although the signal
intensity was detectable at 20 ng/mL, the %
accuracy dropped below 100 ± 20%. Hence, for
LC-MS assay, 10 ng/mL and 20 ng/mL were
considered as LLOD and LLOQ, respectively.
The tandem UV absorbance linearity equation
(Y = 162.86X) was also found to have
r2 = 0.9999 with average accuracy in the range
of 90.84 ± 6.60% to 100.90 ± 0.31%.

Oxidative degradation studies
Finally, lonidamine was subjected to oxidizing
degradation using concentrated H2O2 with a
sample volume of 10 mL (27,28). Samples were
subjected to temperature treatment at 40 °C.
Samples (100 µL) were withdrawn at specific
time (0, 6, 24, and 48 h) points, centrifuged at
15,700 g for 10 min, and subjected to LC-MS runs
to identify degradation profile.
Statistical analysis
Two tailed student’s t-test was used for the
comparative analysis between data of interest.
Wherever possible data is presented as
mean ± standard deviation along with
the respective P values.

Fig. 1. Representative (A) TIC of lonidamine, (B) XIC-LC-MS chromatogram of lonidamine, (C) tandem HPLC-UV
chromatogram, and (D) corresponding mass spectra of lonidamine with target mass ion (M+H)+ as 321.02 m/z. TIC,
Total Ion chromatogram; XIC, extracted Ion chromatogram; LC-MS, liquid chromatography-mass spectrometry; HPLC,
high-performance liquid chromatography; UV, ultraviolet.
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Table 1. The CV and accuracy for the calibration standards used for plotting calibration curves for lonidamine using
LC-MS runs, and tandem HPLC runs of lonidamine (with UV base detection) for its quantitation. Detection for the
drug molecule was carried out at 230 nm wavelength.
LC-MS
Con.
(ng/mL)

Inter-day, n = 6

Intra-day, n = 2

CV (%)

Area ± SD

CV (%)

Area ± SD

Accuracy (%)
Inter-day, n = 6

Accuracy (%)
Intra-day, n = 2

20

1.61

412178 ± 6618

3.56

416858 ±14826

62.85 ± 1.01

63.56 ± 2.26

40

2.28

1314465 ± 29937

2.23

1335634 ± 29745

100.21 ± 2.28

101.82 ± 2.27

50

1.28

1693037 ± 21619

1.01

1708324 ± 17188

103.30 ± 1.32

104.19 ± 1.05

100

1.30

2877082 ± 37260

3.15

2903429 ± 91380

87.74 ± 1.14

88.54 ± 2.79

500

0.74

18570382 ± 138042

2.10

18667992 ± 392568

113.26 ± 0.84

113.86 ± 2.39

1000

1.27

37098195 ± 471480

1.81

37431582 ± 678901

113.13 ± 1.44

114.15 ± 2.07

2000

0.81

75582289 ± 615255

1.36

76017341 ± 1030986

115.24 ± 0.94

115.91 ± 1.57

5000

1.25

177493941 ± 2220627

1.68

179064161 ± 3005901

108.25 ± 1.35

109.21 ± 1.38

10000

0.87

318617153 ± 2779019

4.16

320582216 ± 13341608

97.16 ± 0.85

97.76 ± 4.07

100

124.7

8032 ± 10020

141.4

4836 ± 6840

49.32 ± 61.57

29.67 ± 42.00

500

7.12

80743 ± 5746

0.41

81475 ± 338

99.16 ± 7.05

100.05 ± 0.41

HPLC-UV

1000

8.70

155543 ± 13533

8.13

140343 ± 11411

95.51 ± 8.31

86.17 ± 7.01

2000

0.39

325148 ± 1266

2.34

324296 ± 7596

99.82 ± 0.38

99.56 ± 2.33

5000

1.75

823416 ± 14412

1.61

819876 ± 13223

101.1 ± 1.76

100.68 ± 1.62

10000

1.08

1624961 ± 17589

1.09

1623112 ± 17635

99.78 ± 1.07

99.66 ± 1.08

Con., Concentration; SD, standard deviation; CV, Coefficient of variance; LC-MS, chromatography-mass
spectrometry; HPLC, high-performance liquid chromatography; UV, ultraviolet.

Fig. 2. Representative XIC-LC-MS for (A) LLOD (S/N: 220) as 10 ng/mL and LLOQ (S/N: 945) as 20 ng/mL for
lonidamine and (B) shows representative LLOD (S/N: 1) as 100 ng/mL and LLOQ (S/N:4) as 500 ng/mL for the
HPLC-UV quantitation method. XIC, Extracted Ion chromatogram; LC-MS, liquid chromatography-mass spectrometry;
LLOD, lower limit of detection; LLOQ, lower limit of quantitation; HPLC, high-performance liquid chromatography;
UV, ultraviolet.

The accuracy% and CV% data for the linearity
curve from LC-MS-UV tandem runs are
summarized in Table 1. In case of HPLC-UV
assay, the % accuracy dropped below 100 ± 20 %
at concentrations below 500 ng/mL. Hence, 100
ng/mL (49.32 % accuracy) and 500 ng/mL
(99.15% accuracy) were considered as LLOD and

LLOQ for the assay. The relative sensitivity of
LC-MS (Fig. 2A) was found to be higher
compared to HPLC-UV (Fig. 2B) detections.
Hence, looking at the % accuracy values for both
LC-MS and HPLC-UV runs, linearity curve was
established in the range of 20 to 10,000 ng/mL
and 500 to 1000 ng/mL, respectively.
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Table 2. The CV and accuracy for random concentrations of lonidamine used for the validation of LC-MS based calibration
curve.
Con.
(ng/mL)

Inter-day, n = 3

Intra-day, n = 2

CV (%)

Area ± SD

CV (%)

Area ± SD

Accuracy (%)
Inter-day (n = 3)

Accuracy (%)
Intra-day (n = 2)

80

2.871

2742049 ± 78827

0.17

2679149 ± 4575

104.52 ± 3.00

102.13 ± 0.17

200

2.26

7360566 ± 166086

4.48

7257893 ± 324949

112.23 ± 2.53

110.67 ± 4.95

3000

2.371

104886880 ± 2482132

1.75

102973246 ±1801549

106.62 ± 2.52

104.67 ± 1.83

8000

1.82

246914062 ± 4488524

2.41

242932821 ± 5858593

94.12 ± 1.71

92.60 ± 2.23

Con., Concentration; SD, standard deviation, CV, Coefficient of variance; LC-MS, chromatography-mass spectrometry.

Fig. 3. (A) Degradation of lonidamine in 1 N HCl at 40 and 80 °C, respectively. *P < 0.05 indicates significant differences
between every two points regarding their corresponding time pint. Overall data suggest that lonidamine was degraded
significantly at 80°C under 1N HCl; (B and C) chromatograms of lonidamine at 40 and 80 °C, respectively, at specific
time points showing the relative degradation pattern in 1 N HCl; and (D) chromatograms of probable degradation peak
vs standard and blank 1 N HCl.

concentrations showed accuracy around
100 ± 20% and CV < 10% shown in Table 3.
This indicates that the present method
of LC-MS may serve to be optimum
for the quantitation of degradation peaks
in the stability-indicating method for
lonidamine.

Validation and stability testing of LC-MS
method for the quantitation of lonidamine
The LC-MS method and the calibration
curve were validated using random known
concentrations of lonidamine. Table 2
shows the data (accuracy% and CV%)
for the validation runs. The accuracy for interand intra-day runs was found to be in
the range of 93.36 ± 1.07% and 115.13 ±
2.50%, respectively. The intra- and inter-day
validation results for random concentrations
showed CV (< 5%) in the range of 0.99 ± 1.16%
to 3.68 ± 1.14%. Furthermore, stability
testing (for freeze-thaw cycles) of lonidamine
solution using four additional random

Forced degradation of lonidamine in the
presence of strong acid.
Due to exposure of lonidamine to 1 N HCl
caused a time-dependent reduction in the
concentration of the parent ion peak. This
reduction was increased on a temperaturedependent basis as shown in Fig. 3.
317
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condition showed a temperature-independent
effect. It was detected that parent ion peak
quantitatively reduced upon incubation of
lonidamine in 1N NaOH. Later, it got
significantly degraded within the first 6 h
(P < 0.05) of incubation at both 40 and 80 °C.
Insignificant (P > 0.05), temperature-dependent
difference was observed in the degradation
profile of lonidamine in presence of 1 N NaOH.
There was a subsequent rise in the degradation
peak (Fig. 4) around 1.66 min for a mass range
of 172 to173 m/z.

Table 3. The CV and accuracy (from LC-MS runs) for
random concentration for lonidamine after freezethaw cycles (n = 2).
Concentrations
(ng/mL)

CV (%)

Accuracy (%)

20

3.41 ± 0.60

62.43 ± 0.89

40

0.78 ± 0.20

99.19 ± 0.30

500

1.59 ± 0.20

108.73 ± 3.68

10000

4.89 ± 0.22

88.59 ± 1.59

CV, Coefficient of variance; LC-MS,
chromatography-mass spectrometry.

liquid

The degradation of lonidamine was relatively
higher at 80 °C (P < 0.05) after 20 h of
incubation.
The overall degradation of
lonidamine was significantly (P < 0.05) higher
at 80 °C in comparison to 40 °C in 1 N HCl.
Degradation peak was also identified in the
mass range 276 to 277 m/z (Fig. 3) at the
retention time of 1.88 min.

Forced degradation of lonidamine in the
presence of a strong oxidizing agent
As shown in Fig. 5, lonidamine gets
forced degraded at 40 °C temperature in
a time-dependent manner with P < 0.05.
It was noted that lonidamine gets
degraded by the end of a 48-h (P < 0.05)
time point. The lonidamine peak gets
significantly reduced at a 48-h time
point and consequently the presence of
production (171 to 172 m/z) peak increases
around Rt = 1.60 min.

Forced degradation of lonidamine in the
presence of a strong base
As shown in Fig. 4, it was observed that
lonidamine gets degraded in basic (1N NaOH)

Fig. 4. (A) Time- and temperature-dependent degradation of lonidamine in the presence of 1 N NaOH. Although it shows
complete degradation within first 6 to 24 h of incubation (**P < 0.01), no temperature-dependent effect was observed;
(B) representative chromatograms of lonidamine showing time-dependent degradation of drug molecule in 1 N NaOH;
and (C) degradation peak of lonidamine vs small standard peak for the drug and blank.
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Fig. 5. (A) Significant time-dependent degradation of lonidamine in H2O2 at 40°C with (B) representative chromatogram
of lonidamine showing time-dependent degradation, and (C) chromatogram of probable degradation product of
lonidamine vs standard and blank H2O2. *P ≤ 0.05 and ***P ≤ 0.001 indicate significant differences.

provided a significant improvement over
previous HPLC based UV detection methods by
detecting and quantitating lower concentrations
(19,22). Ioele et al. (21) provided an HPLC
method with a linear calibration range of 0.5 to
50 µg/mL for lonidamine that was used for the
qualitative impurity analysis which had
relatively, higher LLOD and LLOQ values
compared to the present study. Whereas, this
study provided an online LC-MS method using
high-resolution mass spectrometers systems
with high sensitivity in mass detection
with < 0.5 ppm error as compared to previously
reported runs on HPLC and followed by
separate GC-MS based confirmation of masses.
Milane et al. (22) reported HPLC method for
simultaneous estimation of lonidamine and
paclitaxel from plasma and tissue samples of
animals, where LLOD and LLOQ of 64 and
80 ng/mL was reported. Whereas, the present
study data shows that with LC-MS method can
go as low to 10 and 20 ng/mL for LLOD and
LLOQ values. The previously published HPLC
methods were not stability-indicating in nature.
However, it showed that simple isocratic HPLC
methods could be used for the efficient
estimation of lonidamine in a complex matrix.

DISCUSSION
Lonidamine is a hydrophobic anticancer
molecule. A quantitation assay for lonidamine
was developed using reverse phase
chromatography. Lonidamine standards were
subjected to LC-MS-UV runs using
conventional isocratic elution chromatography
with 50:50 water: acetonitrile with 0.1% formic
acid. The present LC-MS based quantifiable
method for lonidamine is sensitive for
detections and quantitation in the nanogram
concentration range (21). A UV based detection
of eluting lonidamine (10 to 10000 ng/mL)
standards were also used in tandem with mass
spectrometer detection. Our results indicated
that UV based HPLC detection could only
provide accurate outcomes in the concentration
range of 500 to 10000 ng/mL with a CV < 10%
(Table 1). This observation and results are
consistent with previously published work with
low injection volumes (21). The result
suggested that tandem HPLC-UV had higher
values for lower limit of detection (LLOD), and
the lower limit of quantitation (LLOQ) (Fig.
2B) as compared to LC-MS (Fig. 2A). This also
confirms that the current LC-MS method
319
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To the best of our knowledge, this is the first
reported LC-MS method for studying the
degradation of lonidamine. This indicated that
the present LC-MS method provides a simple
robust and high sensitivity-based edge for
mapping force degradation rates of lonidamine
under various stress conditions.
The LC-MS (without UV detections) based
linearity curve obtained for lonidamine
described above were subjected to validation
study using random (low, medium, high, and
ultra-high) concentration ranges, as shown in
Table 2. Intra- and inter-day validation results
for random concentrations showed CV < 5%.
The accuracy% for these validation standards
for inter- and intra-day was found to be around
100 ± 20%. These studies indicated that the
calibration curves are robust and with high
accuracy as per the ICH guidelines and
previously published reports (24,29-31).
Linearity and validation study of linearity
provides a necessary baseline for the stability of
drug under ambient room temperature
conditions. Further, the stability test for four
random concentrations (Table 3) also supported
the validation data performed by carrying out
freeze-thaw cycles. It was observed that the
lonidamine molecule has excellent stability at
freezing and ambient room temperature at low
and high concentrations, which is consistent
with the previous report (21). Hence, the LCMS based sensitive quantitation assay could be
used for further analysis of the degradation of
lonidamine under various forced degradation
conditions.
Previous studies have shown that lonidamine
(solid and solution) degrades in the presence of
heat and light. It provides the necessary
information to show that this molecule in the
solution state is thermally stable at 21 and
40 °C. Lonidamine thermally stressed at 70 °C
shows the degradation peak of the drug.
Whereas, the solid lonidamine showed high
stability at 60 and 100 °C and authors were able
to perform only a small part of forced
degradation studies (17,27). The detailed
understanding of the stability of the lonidamine
solution state in the presence of an external
stress inducer becomes important. Hence, we
performed temperature-dependent degradation
of lonidamine in the presence of strong acidic

(1 N HCl), basic (1 N NaOH), and oxidizing
(H2O2) conditions.
To quantitatively estimate the degradation
profile of lonidamine in the presence of a strong
acid, we placed two vials containing 10 mL of
acidified (treated with 1 N HCl) lonidamine
solution in a water bath maintained at 40 and
80 °C. A time-dependent decrease in the
concentration of lonidamine could be observed
in Fig. 3A. There was a significant increase in
the degradation rate due to a temperature
increase to 80 °C. This could also be confirmed
from the stepwise reduction in lonidamine LCMS chromatogram peaks under two
temperature conditions, as shown in Fig. 3B
and C. This indicates that the degradation rate
of lonidamine could get affected by high
temperatures and strong acid. Lonidamine is
degraded under temperature-dependent acid
hydrolysis, and degradation peaks were also
identified. The degradation peaks for
lonidamine after 24 h is shown in Fig. 3D.
Further, a strong degradation of the
lonidamine solution was observed with 1 N
NaOH. It was observed that a strong base could
cause significant damage to the structural
integrity of lonidamine (Fig. 4A and B). Later,
there was a dramatic reduction in the peak of
lonidamine and a subsequent rise in the
degradation peak (Fig. 4C). However, all the
values are lesser then quantitation limits, hence
we can consider complete degradation of the
lonidamine.
Lonidamine degraded at both 40 and 80 °C
under acidic and basic conditions. Taking this
factor into consideration, lonidamine was
treated with H2O2 and incubated at 40 °C in a
water bath. The degradation rate of lonidamine
was assessed at predetermined time points as
shown in Fig. 5A and B. There was a significant
degradation by the end of the 48-h time point.
A degradation peak could be mapped as shown
in Fig. 5C. The present LC-MS method could
detect both the parent and degradation peaks (in
the presence of 1 N HCl, 1 N NaOH, and H2O2)
in a single run. The peaks of the parent ion
remained uninterrupted by degradation.
The
estimation
of
degradation
chromatogram was carried out in an extremely
accurate manner with an error of < 0.5 ppm.
These results showed that lonidamine gets
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degraded in the presence of an acid, base, and
strong oxidation conditions. Moreover, it was
possible to detect the degradation peak of
the parent molecule, which indicates that the
LC-MS method presented in this study is
stability indicating for lonidamine.

designing experiments, data collection,
analysis, writing, and editing the manuscript.
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